The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Open accessAbstract
BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mardis et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“In an AML case with an IDH1 mutation that was sequenced in its entirety (Mardis et al., 2009), there were a relatively small total number of somatic, non-synonymous mutations.”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [170]
In the citing paper
“the lack of evidence that 2HG was acting as a mutagen (Mardis et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [129]
In the citing paper
“Treatment of AML with targeted therapies is particularly promising due to the fact that AMLs have far fewer mutations than most other adult cancers, with an average of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas Research Network, 2013).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Mardis et al, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Cited by
Sorted by citations
Items 301–400 of 1,003
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylationPreprint
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 183
Haage, V. C., Semtner, M., Vidal, R. O., Pérez-Hernández, D., Pong, W. W., Chen, Z., Hambardzumyan, D., Magrini, V. J., Ly, A., Walker, J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0665-y · Cited by 182
Self-citationPHF6 mutations in adult acute myeloid leukemia
Vlierberghe, P. V., Patel, J. L., Abdel-Wahab, O. I., Lobry, C., Hedvat, C. V., Balbı́n, M., Nicolas, C., Páyer, Á. R., Fernandez, H. F., Tallman, M. S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.247 · Cited by 181
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
Carbonneau, M., M. Gagné, L., Lalonde, M.-E., Germain, M.-A., Motorina, A., Guiot, M.-C., Secco, B., Vincent, E. E., Tumber, A., Hulea, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms12700 · Cited by 180
Chou, W.-C., Lei, W.-C., Ko, B., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Wu, S.-J., Huang, S.-Y., et al. (2010) · Leukemia · doi:10.1038/leu.2010.267 · Cited by 180
Kluk, M., Lindsley, R. C., Aster, J. C., Lindeman, N. I., Szeto, D. P., Hall, D., & Kuo, F. C. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.02.003 · Cited by 180
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
Recent developments in myelodysplastic syndromes
Bejar, R. L., & Steensma, D. P. (2014) · Blood · doi:10.1182/blood-2014-04-522136 · Cited by 179
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation
Patel, K. P., Ravandi, F., Ma, D., Paladugu, A. V., Barkoh, B. A., Medeiros, L. J., & Luthra, R. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpd7nr2rmnqdvf · Cited by 179
Tefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. D. (2011) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 179
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Pusch, S., Krausert, S., Fischer, V., Balß, J., Ott, M., Schrimpf, D., Capper, D., Sahm, F., Eisel, J., Beck, A.-C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1677-y · Cited by 179
Cherry, E. M., Abbott, D., Amaya, M. L., McMahon, C. M., Schwartz, M., Rosser, J. A., Sato, A., Schowinsky, J. T., Sheth, A. I., Minhajuddin, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005538 · Cited by 179
PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis
Zhang, B., Zheng, A., Hydbring, P., Ambroise, G., Ouchida, A. T., Goiny, M., Vakifahmetoglu-Norberg, H., & Norberg, E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.067 · Cited by 178
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 178
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
von Deimling, A., Korshunov, A., & Hartmann, C. J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00454.x · Cited by 178
The clinical impact of the molecular landscape of acute myeloid leukemia
Käyser, S., & Levis, M. J. (2023) · Haematologica · doi:10.3324/haematol.2022.280801 · Cited by 178
Nuclear factor I/B is an oncogene in small cell lung cancerPreprint
Dooley, A. L., Winslow, M. M., Chiang, D. Y., Banerji, S. O., Stransky, N., Dayton, T. L., Snyder, E. L., Senna, S., Whittaker, C. A., Bronson, R. T., et al. (2011) · Genes & Development · doi:10.1101/gad.2046711 · Cited by 177
Metabolic analysis as a driver for discovery, diagnosis, and therapy
DeBerardinis, R. J., & Keshari, K. R. (2022) · Cell · doi:10.1016/j.cell.2022.06.029 · Cited by 177
Metabolism unhinged: IDH mutations in cancer
Prensner, J. R., & Chinnaiyan, A. M. (2011) · Nature Medicine · doi:10.1038/nm0311-291 · Cited by 175
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. R. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 175
Altered cancer metabolism in mechanisms of immunotherapy resistance
Ramapriyan, R., Caetano, M. S., Barsoumian, H. B., Mafra, A. C. P., Zambalde, É. P., Menon, H., Tsouko, E., Welsh, J. W., & Cortez, M. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.004 · Cited by 173
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
Leonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.353946 · Cited by 171
Menezes, J., Acquadro, F., Wiseman, M., Goméz-López, G., Salgado, R., Talavera-Casañas, J. G., Buño, I., Cervera, J., Montes‐Moreno, S., Hernández‐Rivas, J. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.283 · Cited by 170
Oncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.06.002 · Cited by 169
Farrar, J. E., Schuback, H. L., Ries, R. E., Wai, D., Hampton, O. A., Treviño, L. R., Alonzo, T. A., Auvil, J. M. G., Davidsen, T. M., Gesuwan, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1015 · Cited by 168
Self-citationEmadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 167
Metabolic coordination of cell fate by α-ketoglutarate-dependent dioxygenases
Baksh, S. C., & Finley, L. W. S. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.010 · Cited by 165
Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02492 · Cited by 165
Bacteria-Human Somatic Cell Lateral Gene Transfer Is Enriched in Cancer Samples
Riley, D. R. J., Sieber, K. B., Robinson, K. M., White, J. R., Ganesan, A., Nourbakhsh, S., & Hotopp, J. C. D. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003107 · Cited by 165
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 165
Abel, H., & Duncavage, E. J. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.11.002 · Cited by 164
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 164
An Extensive Network of TET2-Targeting MicroRNAs Regulates Malignant Hematopoiesis
Cheng, J., Guo, S., Chen, S., Mastriano, S., Liu, C., D’Alessio, A. C., Hysolli, E., Guo, Y., Yao, H., Megyola, C. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.050 · Cited by 164
Myeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, J., Gelsi‐Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 163
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Shi, J., Sun, B., Shi, W., Zuo, H., Cui, D., Ni, L., & Chen, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2644-z · Cited by 163
Distinct metabolomic signatures are associated with longevity in humans
Cheng, S. C., Larson, M. G., McCabe, E. L., Murabito, J. M., Rhee, E. P., Ho, J. E., Jacques, P. F., Ghorbani, A., Magnusson, M., Souza, A. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7791 · Cited by 163
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 162
Metabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 162
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Kang, H., Fan, J., Lin, R., Elf, S., Ji, Q., Zhao, L., Jin, L., Seo, J. H., Shan, C., Arbiser, J. L., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.037 · Cited by 162
Dolnik, A., Engelmann, J. C., Scharfenberger‐Schmeer, M., Mauch, J. A., Kelkenberg-Schade, S., Haldemann, B., Fries, T., Krönke, J., Kühn, M. W. M., Paschka, P., et al. (2012) · Blood · doi:10.1182/blood-2011-12-401471 · Cited by 162
Induction of sarcomas by mutant IDH2Preprint
Lü, C., Venneti, S., Akalin, A., Fang, F., Ward, P. S., Dematteo, R. G., Intlekofer, A. M., Chen, C., Ye, J., Hameed, M., et al. (2013) · Genes & Development · doi:10.1101/gad.226753.113 · Cited by 162
Challenges of sequencing human genomes
Koboldt, D. C., Ding, L., Mardis, E. R., & Wilson, R. K. (2010) · Briefings in Bioinformatics · doi:10.1093/bib/bbq016 · Cited by 161
Self-citationUnlocking the potential of retinoic acid in anticancer therapy
Schenk, T., Stengel, S., & Zelent, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.412 · Cited by 160
Link, D. C. (2011) · JAMA · doi:10.1001/jama.2011.473 · Cited by 160
Self-citationThe Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 160
Borodovsky, A., Salmasi, V., Turcan, Ş., Fabius, A. W. M., Baía, G. S., Eberhart, C. G., WEINGART, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A.-T., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1408 · Cited by 158
Li, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., PHILLIPS, H. S., Selfridge, J. M., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 158
Martin, L., Ribas, R., Simigdala, N., Schuster, E. F., Pancholi, S., Tenev, T., Gellert, P., Buluwela, L., Harrod, A., Thornhill, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01864-y · Cited by 158
Masetti, R., Pigazzi, M., Togni, M., Astolfi, A., Indio, V., Manara, E., Casadio, R., Pession, A., Basso, G., & Locatelli, F. (2013) · Blood · doi:10.1182/blood-2012-11-469825 · Cited by 157
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 157
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Yan, H., Bigner, D. D., Velculescu, V. E., & Parsons, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2650 · Cited by 156
The methyltransferase G9a regulates HoxA9-dependent transcription in AMLPreprint
Lehnertz, B., Pabst, C., Yi, L.-Y., Miller, M., Liu, F., Yi, L., Zhang, R., Krošl, J., Yung, E., Kirschner, J., et al. (2014) · Genes & Development · doi:10.1101/gad.236794.113 · Cited by 156
Makishima, H., Jankowska, A. M., McDevitt, M. A., O’Keefe, C. L., Dujardin, S., Cazzolli, H., Przychodzen, B. P., Prince, C. J., Nicoll, J. M., Harish, S., et al. (2011) · Blood · doi:10.1182/blood-2010-06-292433 · Cited by 155
PHGDH amplification and altered glucose metabolism in human melanoma
Mullarky, E., Mattaini, K. R., Heiden, M. G. V., Cantley, L. C., & Locasale, J. W. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00919.x · Cited by 153
Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia
Oakes, C. C., Claus, R., Gu, L., Assenov, Y., Hüllein, J., Zucknick, M., Bieg, M., Brocks, D., Bogatyrova, O., Schmidt, C. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0349 · Cited by 153
Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma
Lee, D., Xu, M., Chiu, D. K., Lai, R. K., Tse, A. P., Li, L. L., Law, C., Tsang, F. H., Wei, L. L., Chan, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90253 · Cited by 153
Holstege, H., Pfeiffer, W., Sie, D., Hulsman, M., Nicholas, T. J., Lee, C. C., Ross, T., Lin, J., Miller, M. A., Ylstra, B., et al. (2014) · Genome Research · doi:10.1101/gr.162131.113 · Cited by 152
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
Frontline treatment of acute myeloid leukemia in adults
Tamamyan, G., Kadia, T. M., Ravandi, F., Borthakur, G. M., Cortes, J. E., Jabbour, E. J., Daver, N. G., Ohanian, M. N., Kantarjian, H. M., & Konopleva, M. Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.004 · Cited by 151
Großmann, V., Kohlmann, A., Eder, C., Haferlach, C., Kern, W., Cross, N. C. P., Haferlach, T., & Schnittger, S. (2011) · Leukemia · doi:10.1038/leu.2011.10 · Cited by 150
Cancer Genomics and Inherited Risk
Stadler, Z. K., Schrader, K. A., Vijai, J., Robson, M. E., & Offit, K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7271 · Cited by 149
Scotland, S., Saland, E., Skuli, N., de Toni, F., Boutzen, H., Micklow, E., Sénégas, I., Peyraud, R., Peyriga, L., Théodoro, F., et al. (2013) · Leukemia · doi:10.1038/leu.2013.107 · Cited by 149
Zhao, A., Zhou, H., Yang, J., Li, M., & Niu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01342-6 · Cited by 153
Analysis of next-generation genomic data in cancer: accomplishments and challenges
Ding, L., Wendl, M. C., Koboldt, D. C., & Mardis, E. R. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq391 · Cited by 148
Self-citationIDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
Bralten, L. B. C., Kloosterhof, N. K., Balvers, R. K., Sacchetti, A., Lapre, L., Lamfers, M. L. M., Leenstra, S., de Jonge, H. R., Kros, J. M., Jansen, E. E. W., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22390 · Cited by 148
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
Jäger, R., Gisslinger, H., Passamonti, F., Rumi, E., Berg, T., Gisslinger, B., Pietra, D., Harutyunyan, A. S., Klampfl, T., Olcaydu, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.99 · Cited by 147
Craddock, C., Quek, L. S., Goardon, N., Freeman, S. D., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D. J., Ivey, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.312 · Cited by 147
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Inborn and acquired metabolic defects in cancer
Frezza, C., Pollard, P. J., & Gottlieb, E. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0728-4 · Cited by 147
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Wang, J.-H., Chen, W., Li, J., Wu, S., Chen, T., Zhu, Y., Zhang, W., Li, Y., Qiu, Y.-P., Zhao, A.-H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315558110 · Cited by 146
Ostronoff, F., Othus, M. K. D., Gerbing, R. B., Loken, M. R., Raimondi, S. C., Hirsch, B. A., Lange, B. J., Petersdorf, S. H., Radich, J. P., Appelbaum, F. R., et al. (2014) · Blood · doi:10.1182/blood-2014-04-570929 · Cited by 146
Update on molecular findings, management and outcome in low-grade gliomas
Bourne, T. D., & Schiff, D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.159 · Cited by 146
Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges
Luthra, R., Chen, H., Roy‐Chowdhuri, S., & Singh, R. R. (2015) · Cancers · doi:10.3390/cancers7040874 · Cited by 146
Morandi, A., Taddei, M. L., Chiarugi, P., & Giannoni, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00040 · Cited by 146
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 145
Personal genome sequencing: current approaches and challengesPreprint
Snyder, M. P., Du, J., & Gerstein, M. (2010) · Genes & Development · doi:10.1101/gad.1864110 · Cited by 145
Existing and Emerging Technologies for Tumor Genomic Profiling
MacConaill, L. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5948 · Cited by 144
Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers
Geiger, T., Madden, S. F., Gallagher, W. M., Cox, J., & Mann, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3711 · Cited by 144
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Stuani, L., Sabatier, M., Wang, F., Poupin, N., Bosc, C., Saland, E., Castelli, F. A., Gales, L., Montersino, C., Boët, E., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200924 · Cited by 143
Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Non-invasive in vivo assessment of IDH1 mutational status in glioma
Chaumeil, M. M., Larson, P. E. Z., Yoshihara, H. A. I., Danforth, O. M., Vigneron, D. B., Nelson, S. J., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2013) · Nature Communications · doi:10.1038/ncomms3429 · Cited by 142
Spencer, D. H., Abel, H., Lockwood, C. M., Payton, J. E., Szankasi, P., Kelley, T. W., Kulkarni, S., Pfeifer, J. D., & Duncavage, E. J. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.08.001 · Cited by 142
Self-citationDNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Hélevaut, N., Gardin, C., Cayuela, J., Hayette, S., Reman, O., Contentin, N., et al. (2012) · Leukemia · doi:10.1038/leu.2011.382 · Cited by 139
Green, C. L., Evans, C. M., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Blood · doi:10.1182/blood-2010-02-270926 · Cited by 139
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 139
Pathophysiology of Acute Myeloid Leukemia
Wachter, F., & Pikman, Y. (2024) · Acta Haematologica · doi:10.1159/000536152 · Cited by 140
Metabolic alterations in cancer cells and therapeutic implications
Hammoudi, N., Ahmed, K. B. R., Garcı́a-Prieto, C., & Huang, P. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10267 · Cited by 137
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
Chiang, S., Weigelt, B., Wen, H., Pareja, F. G., Raghavendra, A., Martelotto, L. G., Burke, K. A., Basili, T., Li, A., Geyer, F. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0298 · Cited by 137
Organic Bioelectronic Devices for Metabolite Sensing
Koklu, A., Ohayon, D., Wustoni, S., Druet, V., Saleh, A., & Inal, S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00395 · Cited by 138
Genomic landscape of liposarcoma
Kanojia, D., Nagata, Y., Garg, M., Lee, D. H., Sato, A., Yoshida, K., Sato, Y., Sanada, M., Mayakonda, A., Bartenhagen, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6464 · Cited by 136
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 135
DNA methylation-based classification of sinonasal undifferentiated carcinoma
Doğan, S., Vasudevaraja, V., Xu, B., Serrano, J., Ptashkin, R. N., Jung, H. J., Chiang, S., Jungbluth, A. A., Cohen, M. A., Ganly, I., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0285-x · Cited by 135
Clonal evolution of acute myeloid leukemia from diagnosis to relapse
Vosberg, S., & Greif, P. A. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22806 · Cited by 135
Advances in epigenetic therapeutics with focus on solid tumors
Jin, N. Y., George, T. L., Otterson, G. A., Verschraegen, C. F., Wen, H., Carbone, D. P., Herman, J. G., Bertino, E. M., & He, K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01069-7 · Cited by 135
Murugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 135
Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
Peddi, P. F., Ellis, M. J., & Ma, C. X. (2011) · International Journal of Breast Cancer · doi:10.1155/2012/217185 · Cited by 134
Capper, D., Reuß, D., Schittenhelm, J., Hartmann, C. J., Bremer, J., Sahm, F., Harter, P. N., Jeibmann, A., & von Deimling, A. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0770-2 · Cited by 134
Metadata
- Authors
- Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J., Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E., McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J., Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J., Graubert, T. A., DiPersio, J. F., Wilson, R. K., & Ley, T. J.
- Affiliations
- Washington University in St. Louis (US)
- Alvin J. Siteman Cancer Center (US)
- ORCID
- Mardis, Elaine R.
- Ding, Li
- Larson, David E.
- McLellan, Michael D.
- Chen, Ken
- Koboldt, Daniel C.
- Fulton, Robert S.
- McGrath, Sean D.
- Magrini, Vincent J.
- Vickery, Tammi L.
- Wylie, Todd
- Walker, Jason
- McMichael, Joshua F.
- Pohl, Craig S.
- Tang, Yuzhu
- Ries, Rhonda E.
- Payton, Jacqueline E.
- Tomasson, Michael H.
- Watson, Mark A.
- Heath, Sharon
- Link, Daniel C.
- Walter, Matthew J.
- Graubert, Timothy A.
- DiPersio, John F.
- Wilson, Richard K.
- Ley, Timothy J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1058-1066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3201812
- OpenAlex
- W2134061682
- Cited by
- 2,219
- References
- 31
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 57 · 2023: 76 · 2022: 81 · 2021: 107 · 2020: 104 · 2019: 115 · 2018: 120 · 2017: 126 · 2016: 136 · 2015: 154 · 2014: 163 · 2013: 197 · 2012: 251
- FWCI
- 154.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (U54HG003079)
- National Cancer Institute (P01CA101937)
- National Center for Research Resources (UL1RR024992)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, somatic mutations, IDH1 mutation, NPM1 mutation, NRAS mutation, cytogenetically normal AML, tumor genome sequencing
- MeSH terms
- Nucleophosmin, Adult, DNA Mutational Analysis, Female, Gene Frequency, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Genome, Human, Point Mutation, Sequence Analysis, DNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
